Medicilon(SH:688202) Xin Lang Cai Jing·2026-01-05 02:25Group 1 - The core point of the article highlights the performance of Shanghai Medicy Biopharmaceutical Co., Ltd., which saw a stock increase of 5.27% to 59.37 CNY per share, with a total market capitalization of 7.976 billion CNY [1] - The company, established on February 2, 2004, and listed on November 5, 2019, specializes in providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1] - The revenue composition of the company is primarily from preclinical research (50.34%) and drug discovery and pharmaceutical research (49.64%), with a negligible contribution from other sources (0.01%) [1] Group 2 - From the perspective of fund holdings, Wanjia Fund has a significant position in Medicy, with its Wanjia National Index 2000 ETF (159628) holding 99,500 shares, representing 0.54% of the fund's net value, making it the second-largest holding [2] - The Wanjia National Index 2000 ETF has a total scale of 1.286 billion CNY and has achieved a year-to-date return of 34.55%, ranking 1391 out of 4189 in its category [2] - The fund manager, Yang Kun, has been in position for 6 years and 76 days, with the best fund return during his tenure being 81.38% and the worst being -32.3% [2]